Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study

PURPOSE: BRAF and MEK inhibitors significantly improved the prognosis of metastatic melanoma. Nevertheless, initial treatment response may be only temporary. Liquid biopsies (LB) offer a possibility to monitor patients by measuring circulating tumor DNA (ctDNA). We sought to find out whether ctDNA c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Forschner, Andrea, Weißgraeber, Stephanie, Hadaschik, Dirk, Schulze, Martin, Kopp, Maria, Kelkenberg, Sabine, Sinnberg, Tobias, Garbe, Claus, Biskup, Saskia, Battke, Florian
Format: Artigo
Idioma:Inglês
Publicat: Dove 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280255/
https://ncbi.nlm.nih.gov/pubmed/32581559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S248237
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars